These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 22607851)

  • 21. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design for programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock (PROVIDE) study.
    Saeed M; Razavi M; Neason CG; Petrutiu S
    Europace; 2011 Nov; 13(11):1648-52. PubMed ID: 21784746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Subcutaneous implantable cardioverter-defibrillators].
    Furlanello F; Lupo PP; Ali H; Cappato R
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):41S-45S. PubMed ID: 23096374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biventricular stimulation therapy in patients with heart failure and tachycardic arrhythmias. Indications--results--prospects].
    Trappe HJ
    Biomed Tech (Berl); 2002 Oct; 47(9-10):243-9. PubMed ID: 12369212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age dependent efficacy of implantable cardioverter-defibrillator treatment: observations in 450 patients over an 11 year period.
    Trappe HJ; Pfitzner P; Achtelik M; Fieguth HG
    Heart; 1997 Oct; 78(4):364-70. PubMed ID: 9404252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis.
    Aizer A; Stern EH; Gomes JA; Teirstein AS; Eckart RE; Mehta D
    Am J Cardiol; 2005 Jul; 96(2):276-82. PubMed ID: 16018857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.
    Olde Nordkamp LR; Dabiri Abkenari L; Boersma LV; Maass AH; de Groot JR; van Oostrom AJ; Theuns DA; Jordaens LJ; Wilde AA; Knops RE
    J Am Coll Cardiol; 2012 Nov; 60(19):1933-9. PubMed ID: 23062537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].
    Kozák M; Krivan L; Semrád B
    Vnitr Lek; 2001 Jun; 47(6):361-70. PubMed ID: 11494881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience.
    Aydin A; Hartel F; Schlüter M; Butter C; Köbe J; Seifert M; Gosau N; Hoffmann B; Hoffmann M; Vettorazzi E; Wilke I; Wegscheider K; Reichenspurner H; Eckardt L; Steven D; Willems S
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):913-9. PubMed ID: 22923274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Implantable cardioverter-defibrillators in patients resuscitated from sudden death and in patients with sustained refractory ventricular tachycardia].
    Adragão P; Parreira L; Neves J; Morgado F; Abecassis M; Almeida M; Martins D; Bonhorst D; Seabra-Gomes R
    Rev Port Cardiol; 1996 Mar; 15(3):195-206, 179, 181. PubMed ID: 8634168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease.
    Khanna AD; Warnes CA; Phillips SD; Lin G; Brady PA
    Am J Cardiol; 2011 Sep; 108(5):729-34. PubMed ID: 21684513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study.
    de Bie MK; Lekkerkerker JC; van Dam B; Gaasbeek A; van Buren M; Putter H; van Erven L; Bax JJ; Schalij MJ; Rabelink TJ; Jukema JW
    Curr Med Res Opin; 2008 Aug; 24(8):2151-7. PubMed ID: 18561878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sudden cardiac death: New approaches for implantable cardioverter-defibrillators (ICDs).
    Cappato R; Ali H
    Int J Cardiol; 2017 Jun; 237():38-41. PubMed ID: 28377192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of the PRAETORIAN score for defibrillation test success in patients with subcutaneous ICD: A subanalysis of the PRAETORIAN-DFT trial.
    Knops RE; El-Chami MF; Marquie C; Nordbeck P; Quast ABE; Tilz RR; Brouwer TF; Lambiase PD; Cassidy CJ; Boersma LVA; Burke MC; Pepplinkhuizen S; de Veld JA; de Weger A; Bracke FALE; Manyam H; Probst V; Betts TR; Bijsterveld NR; Defaye P; Demming T; Elders J; Field DC; Ghani A; Golovchiner G; de Jong JSSG; Lewis N; Marijon E; Martin CA; Miller MA; Shaik NA; van der Stuijt W; Kuschyk J; Olde Nordkamp LRA; Arya A; Borger van der Burg AE; Boveda S; van Doorn DJ; Glikson M; Kaiser L; Maass AH; van Woerkens LJPM; Zaidi A; Wilde AAM; Smeding L
    Heart Rhythm; 2024 Jun; 21(6):836-844. PubMed ID: 38336193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain.
    van Rees JB; Borleffs CJ; Thijssen J; de Bie MK; van Erven L; Cannegieter SC; Bax JJ; Schalij MJ
    Europace; 2012 Jan; 14(1):66-73. PubMed ID: 21920909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.
    Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J
    Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.